Truist Financial Reaffirms Buy Rating for UiPath (NYSE:PATH)

Truist Financial restated their buy rating on shares of UiPath (NYSE:PATHFree Report) in a report published on Wednesday, Benzinga reports. The brokerage currently has a $32.00 price objective on the healthcare company’s stock.

Other analysts also recently issued reports about the company. Royal Bank of Canada reissued a sector perform rating and issued a $29.00 price objective on shares of UiPath in a research note on Wednesday. Needham & Company LLC reissued a buy rating and issued a $30.00 price objective on shares of UiPath in a research note on Wednesday. Canaccord Genuity Group increased their price objective on UiPath from $27.00 to $30.00 and gave the stock a buy rating in a research note on Friday, March 15th. Evercore ISI increased their price target on UiPath from $24.00 to $27.00 and gave the company an in-line rating in a research report on Thursday, March 14th. Finally, Barclays increased their price target on UiPath from $23.00 to $25.00 and gave the company an equal weight rating in a research report on Friday, March 15th. Nine analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, UiPath has an average rating of Hold and a consensus target price of $27.44.

View Our Latest Analysis on UiPath

UiPath Stock Down 2.1 %

Shares of UiPath stock opened at $22.98 on Wednesday. The company has a market cap of $13.01 billion, a PE ratio of -135.14 and a beta of 0.97. UiPath has a 52 week low of $12.38 and a 52 week high of $27.87. The business has a 50 day moving average price of $23.56 and a 200-day moving average price of $20.84.

Insider Buying and Selling at UiPath

In other UiPath news, Director Rich Wong sold 200,000 shares of the firm’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at $9,928,144.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Rich Wong sold 200,000 shares of UiPath stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.12, for a total value of $4,624,000.00. Following the transaction, the director now owns 429,418 shares in the company, valued at $9,928,144.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Ashim Gupta sold 70,000 shares of UiPath stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.02, for a total value of $1,611,400.00. Following the completion of the transaction, the chief financial officer now owns 788,148 shares in the company, valued at approximately $18,143,166.96. The disclosure for this sale can be found here. Insiders have sold 427,000 shares of company stock worth $9,784,110 over the last 90 days. Corporate insiders own 31.03% of the company’s stock.

Institutional Trading of UiPath

Several large investors have recently modified their holdings of the business. PNC Financial Services Group Inc. grew its stake in shares of UiPath by 50.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 19,135 shares of the healthcare company’s stock worth $475,000 after purchasing an additional 6,385 shares during the last quarter. Vanguard Group Inc. boosted its position in UiPath by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 38,084,858 shares of the healthcare company’s stock valued at $946,028,000 after acquiring an additional 334,085 shares in the last quarter. Gerber LLC bought a new stake in UiPath during the 4th quarter valued at approximately $455,000. Sierra Summit Advisors LLC bought a new stake in UiPath during the 4th quarter valued at approximately $5,897,000. Finally, GSA Capital Partners LLP bought a new stake in UiPath during the 4th quarter valued at approximately $259,000. 59.04% of the stock is owned by institutional investors.

UiPath Company Profile

(Get Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

See Also

Analyst Recommendations for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.